ValiRx cervical cancer test to hit Europe
This article was originally published in Clinica
Executive Summary
Cancer therapeutics specialist ValiRx is set to distribute Clarity Imaging International's Geneotype diagnostic test kit for human papillomavirus (HPV) in the major European markets. The deal, of which financial terms were not disclosed, will see London, UK-based ValiRx distribute the test to the countries belonging to the European Economic Area - including France, Germany, Spain and the UK - and Switzerland. According to ValiRx, the Geneotype kit can test for 39 subtypes of HPV - screening of HPV is reported to be superior to current PAP smear tests which looks out for pre-cancerous cervical cells.